Allscripts Healthcare Solutions Inc Stock Research

Market Summary

USD11.90+0.01

Market Closed

0.08%

MDRX Stock Price

MDRX RSI Chart

MDRX Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

22.47

Price/Sales (Trailing)

1.63

EV/EBITDA

2.9

Price/Free Cashflow

8.81

MDRX Price/Sales (Trailing)

MDRX Profitability

Operating Margin

-4.40%

EBT Margin

14.59%

Return on Equity

5.15%

Return on Assets

3.59%

Free Cashflow Yield

11.35%

MDRX Fundamentals

MDRX Revenue

Revenue (TTM)

837.2M

Revenue Y/Y

5.01%

Revenue Q/Q

0.68%

MDRX Earnings

Earnings (TTM)

60.6M

Earnings Y/Y

-10.21%

Earnings Q/Q

122.69%

Price Action

52 Week Range

11.5719.77

(Low)(High)

Last 7 days

-1.6%

Last 30 days

-3.2%

Last 90 days

-29.4%

Trailing 12 Months

-29.9%

MDRX Financial Health

Current Ratio

3.2

Debt/Equity

0.02

Debt/Cashflow

7.14

MDRX Investor Care

Buy Backs (1Y)

10.86%

Diluted EPS (TTM)

0.39

Peers (Alternatives to Allscripts Healthcare Solutions)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	448.8B	335.9B	-0.30%	-2.84%	21.68	1.34	12.90%	18.65%
VEEV	26.0B	2.2B	-6.51%	-0.02%	53.24	12.05	16.44%	14.11%
MID-CAP
CHNG	9.0B	-	11.88%	31.28%	-116.8	2.57	-	-
TDOC	3.7B	2.5B	-11.99%	-32.20%	-0.53	1.5	15.22%	-2.18%
OMCL	3.3B	1.3B	24.63%	-32.85%	583.74	2.54	14.48%	-92.74%
SMALL-CAP
PHR	1.6B	280.9M	-4.19%	67.00%	-9.15	5.74	31.74%	-49.07%
MDRX	1.4B	837.2M	-3.25%	-29.92%	22.47	1.63	3.88%	-92.18%
NXGN	1.0B	653.2M	-10.02%	-15.43%	-381.88	1.55	9.53%	-264.03%
CCRN	920.4M	2.6B	15.69%	53.16%	5.9	0.35	23.61%	-10.67%
SLP	897.5M	54.4M	8.85%	-3.12%	85.74	16.5	9.18%	-9.20%
HSTM	717.7M	270.4M	-7.09%	16.48%	60.71	2.65	4.56%	83.36%
HCAT	616.5M	282.0M	-8.00%	-22.47%	-4.16	2.19	10.96%	-0.57%
CPSI	364.2M	335.0M	-6.83%	-22.50%	33.6	1.09	15.32%	-51.61%

Financials for Allscripts Healthcare Solutions

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	0.9%	837	830	820	811	806
Cost Of Revenue	-0.7%	874	881	882	883	444
Gross Profit	2.2%	655	641	630	620	362
S&GA Expenses	1.4%	360	355	323	314	181
R&D Expenses	1.3%	201	198	196	194	117
EBITDA	-0.4%	300	301	164	202	-
EBITDA Margin	-1.2%	0.36*	0.36*	0.16*	0.16*	-
Earnings Before Taxes	-2.1%	122	125	160	162	-11.57
EBT Margin	2.1%	0.15*	0.14*	0.15*	0.13*	-
Interest Expenses	-21.4%	9.00	11.00	12.00	13.00	16.00
Net Income	-2.7%	61.00	62.00	148	134	775
Net Income Margin	-3.5%	0.07*	0.08*	0.14*	0.11*	-
Free Cahsflow	-14.9%	155	182	-16.16	-80.72	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	-1.4%	1,691	1,714	2,430	2,425	2,484
Current Assets	-2.2%	811	829	1,541	761	805
Cash Equivalents	-1.5%	493	500	83.00	133	142
Net PPE	-21.8%	12.00	15.00	9.00	10.00	54.00
Goodwill	0.0%	524	524	520	507	974
Liabilities	-0.8%	514	518	1,077	1,017	1,066
Current Liabilities	-1.3%	253	256	647	547	567
Long Term Debt	-	26.00	-	-	-	-
LT Debt, Non Current	0.2%	200	200	377	350	373
Shareholder's Equity	-1.6%	1,177	1,196	1,353	1,408	1,419
Retained Earnings	2.0%	753	739	803	13.00	680
Additional Paid-In Capital	0.0%	1,924	1,924	1,922	1,962	1,952
Accumulated Depreciation	-	323	-	-	-	-
Shares Outstanding	-1.4%	109	111	115	116	123

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-14.7%	161	189	-10.74	-75.43	-319
Share Based Compensation	1.2%	46.00	46.00	39.00	35.00	17.00
Cashflow From Investing	1.7%	646	635	-37.38	-12.17	1,625
Cashflow From Financing	2.2%	-520	-532	-314	-258	-1,315
Buy Backs	13.4%	286	252	467	417	589

Risks for MDRX

What is the probability of a big loss on MDRX?

91.5%

Probability that Allscripts Healthcare Solutions stock will be more than 20% underwater in next one year

58.1%

Probability that Allscripts Healthcare Solutions stock will be more than 30% underwater in next one year.

21.9%

Probability that Allscripts Healthcare Solutions stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MDRX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Allscripts Healthcare Solutions was unfortunately bought at previous high price.

Drawdowns

Returns for MDRX

Cumulative Returns on MDRX

-1.5%

10-Year Cumulative Returns

-1.6%

7-Year Cumulative Returns

-1.3%

5-Year Cumulative Returns

21.0%

3-Year Cumulative Returns

What are the long-term rolling returns for MDRX?

FIve years rolling returns for Allscripts Healthcare Solutions.

Annualized Returns

Which funds bought or sold MDRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-23	ROYCE & ASSOCIATES LP	added	144	528,466	1,180,230	0.01%
2023-05-23	Brookfield Corp /ON/	reduced	-36.77	-514,359	452,013	-%
2023-05-23	Front Row Advisors LLC	unchanged	-	-1,000	3,000	-%
2023-05-22	PUTNAM INVESTMENTS LLC	added	456	6,637,200	8,767,670	0.01%
2023-05-22	AMERIPRISE FINANCIAL INC	added	15.19	-1,469,470	8,464,530	-%
2023-05-18	JPMORGAN CHASE & CO	reduced	-43.55	-18,527,100	13,285,900	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-32.51	-975,000	973,000	-%
2023-05-17	Advisory Services Network, LLC	unchanged	-	-1,606	4,568	-%
2023-05-17	Thrivent Financial for Lutherans	reduced	-3.39	-564,000	1,413,000	-%
2023-05-17	VIRGINIA RETIREMENT SYSTEMS ET AL	added	110	1,119,570	1,896,300	0.02%

Latest Funds Activity

Are funds buying MDRX calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own MDRX

No. of Funds

Allscripts Healthcare Solutions News

Schedule 13G FIlings of Allscripts Healthcare Solutions

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 10, 2023	dimensional fund advisors lp	8.5%	9,277,320	SC 13G/A
Feb 09, 2023	vanguard group inc	12.40%	13,550,569	SC 13G/A
Jan 26, 2023	blackrock inc.	19.1%	20,902,942	SC 13G/A
Jan 20, 2023	blackrock inc.	19.1%	20,902,942	SC 13G/A
Feb 09, 2022	vanguard group inc	10.82%	13,268,135	SC 13G/A
Feb 08, 2022	dimensional fund advisors lp	8.2%	10,090,569	SC 13G/A
Jan 28, 2022	blackrock inc.	19.5%	23,846,502	SC 13G/A
Apr 12, 2021	wellington management group llp	3.78%	5,292,953	SC 13G/A
Feb 12, 2021	dimensional fund advisors lp	6.9%	10,939,535	SC 13G/A
Feb 10, 2021	vanguard group inc	10.11%	15,973,325	SC 13G/A

MDRX Fair Value

Allscripts Healthcare Solutions fair value in different scenarios

The table shows the Fair Value estimates for Allscripts Healthcare Solutions for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	4.48 -62.35%	5.11 -57.06%	6.43 -45.97%	7.64 -35.80%	9.54 -19.83%
Current Inflation	4.40 -63.03%	5.00 -57.98%	6.20 -47.90%	7.30 -38.66%	8.82 -25.88%
Very High Inflation	4.31 -63.78%	4.85 -59.24%	5.91 -50.34%	6.87 -42.27%	7.96 -33.11%

Historical Allscripts Healthcare Solutions Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Allscripts Healthcare Solutions

View All Filings

Date Filed	Form Type	Document
May 26, 2023	4	Insider Trading
May 19, 2023	8-K	Current Report
May 11, 2023	4	Insider Trading
May 11, 2023	4	Insider Trading
May 11, 2023	4	Insider Trading
May 11, 2023	NT 10-Q	NT 10-Q
May 03, 2023	4	Insider Trading
May 03, 2023	4	Insider Trading
May 03, 2023	4	Insider Trading
Apr 03, 2023	4	Insider Trading

Latest Insider Trading transactions for MDRX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-10	Poulton Richard J.	sold (taxes)	-157,140	11.9	-13,205	ceo
2023-05-10	Vakharia Tejal	sold (taxes)	-37,711	11.9	-3,169	svp general counsel
2023-05-10	Hammond Lisa	sold (taxes)	-28,000	11.9	-2,353	svp & chief hr officer
2023-05-02	Langan Thomas	sold (taxes)	-22,999	12.15	-1,893	president and cco
2023-05-02	Jones Leah	sold (taxes)	-27,009	12.15	-2,223	chief financial officer
2023-05-01	Vakharia Tejal	sold (taxes)	-53,891	12.53	-4,301	svp general counsel
2023-05-01	Jones Leah	sold (taxes)	-86,031	12.53	-6,866	chief financial officer
2023-05-01	Langan Thomas	sold (taxes)	-117,206	12.53	-9,354	president and cco
2023-04-01	Vakharia Tejal	sold (taxes)	-33,447	13.05	-2,563	svp general counsel
2023-04-01	Langan Thomas	sold (taxes)	-193,218	13.05	-14,806	president and cco

About Allscripts Healthcare Solutions

Richard J. Poulton

www.allscripts.com

8000

Allscripts Healthcare Solutions, Inc., together with its subsidiaries, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. Allscripts Healthcare Solutions, Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

MDRX Income Statement

2022-09-30

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Revenue from contract with customers	$ 151,922	$ 144,668	$ 445,492	$ 419,526
Cost of revenue:
Total cost of revenue	68,486	75,028	209,093	218,550
Gross profit	83,436	69,640	236,399	200,976
Selling, general and administrative expenses	32,518	27,392	133,683	87,680
Research and development	23,681	21,042	69,851	62,644
Asset impairment charges	0	359	0	531
Amortization of intangible and acquisition-related assets	2,236	2,363	6,648	7,090
Income from operations	25,001	18,484	26,217	43,031
Interest expense	(1,246)	(3,617)	(5,269)	(9,709)
Other income, net	1,655	4,493	3,800	21,819
Gain on sale of businesses, net	0	8,363	0	8,363
Equity in net loss income of unconsolidated investments	(617)	(257)	(1,222)	(321)
Income from continuing operations before income taxes	24,793	27,466	23,526	63,183
Income tax (provision) benefit	(13,868)	(7,190)	9,132	(12,464)
Income from continuing operations, net of tax	10,925	20,276	32,658	50,719
Income (loss) from discontinued operations	(434)	(6,187)	(9,252)	(6,545)
Gain on sale of discontinued operations	5,174	0	7,939	647
Income tax effect on discontinued operations	(1,137)	2,091	(57,986)	2,342
Income (loss) from discontinued operations, net of tax	3,603	(4,096)	(59,299)	(3,556)
Net income (loss)	$ 14,528	$ 16,180	$ (26,641)	$ 47,163
Basic
Continuing operations	$ 0.10	$ 0.16	$ 0.29	$ 0.38
Discontinued operations	0.03	(0.03)	(0.52)	(0.03)
Net earnings (loss) per Common Share	0.13	0.13	(0.23)	0.35
Diluted
Continuing operations	0.09	0.15	0.25	0.36
Discontinued operations	0.03	(0.03)	(0.44)	(0.03)
Net earnings (loss) per Common Share	$ 0.12	$ 0.12	$ (0.19)	$ 0.33
Provider [Member]
Revenue:
Revenue from contract with customers	$ 122,811	$ 118,179	$ 360,415	$ 345,253
Cost of revenue:
Total cost of revenue	57,252	61,606	172,595	180,566
Payer & Life Sciences [Member]
Revenue:
Revenue from contract with customers	29,111	26,489	85,077	74,273
Cost of revenue:
Total cost of revenue	$ 11,234	$ 13,422	$ 36,498	$ 37,984

MDRX Balance Sheet

2022-09-30

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 492,597	$ 132,517
Restricted cash	1,307	1,308
Accounts receivable, net of allowance of $12,868 and $13,360 as of September 30, 2022 and December 31, 2021, respectively	169,029	171,622
Contract assets, net of allowance of $564 and $576 as of September 30, 2022 and December 31, 2021, respectively	65,453	63,429
Prepaid expenses and other current assets	74,384	60,511
Assets held for sale	8,000	331,955
Total current assets attributable to discontinued operations	810,770	761,342
Fixed assets, net	11,713	9,819
Software development costs, net	78,103	74,688
Intangible assets, net	145,255	149,690
Goodwill	523,927	506,607
Deferred taxes, net	6	0
Contract assets - long-term, net of allowance of $1,201 and $1,534 as of September 30, 2022 and December 31, 2021, respectively	27,957	28,174
Right-of-use assets - operating leases	14,520	18,324
Other assets	78,408	83,429
Long-term assets attributable to discontinued operations	0	793,156
Total assets	1,690,659	2,425,229
Current liabilities:
Accounts payable	12,609	5,281
Accrued expenses	82,917	54,518
Accrued compensation and benefits	33,857	31,055
Deferred revenue	98,930	120,748
Current operating lease liabilities	6,166	6,133
Current liabilities attributable to discontinued operations	18,612	329,347
Total current liabilities attributable to discontinued operations	253,091	547,082
Long-term debt	200,326	350,062
Deferred revenue	3,060	1,839
Deferred taxes, net	8,082	16,625
Long-term operating lease liabilities	12,315	16,754
Other liabilities	36,762	33,823
Long-term liabilities attributable to discontinued operations	0	50,906
Total liabilities	513,636	1,017,091
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of September 30, 2022 and December 31, 2021	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of September 30, 2022 and December 31, 2021; 279,600 and 109,260 shares issued and outstanding as of September 30, 2022, respectively; 276,705 and 116,114 shares issued and outstanding as of December 31, 2021, respectively	2,794	2,766
Treasury stock: at cost, 170,340 and 160,591 shares as of September 30, 2022 and December 31, 2021, respectively	(1,498,836)	(1,321,805)
Additional paid-in capital	1,923,559	1,962,386
Retained earnings	753,392	767,556
Accumulated other comprehensive loss	(3,886)	(2,765)
Total stockholders’ equity	1,177,023	1,408,138
Total liabilities and stockholders’ equity	$ 1,690,659	$ 2,425,229